We've been loosely following Natco, an Indian company making a generic version of Copaxone which it sells in India for 1/3 the price of the name brand drug. They just successfully blocked a patent in India for Copaxone.
Teva Pharmaceuticals, the maker of Copaxone, is known worldwide as a manufacturer of generic drugs. I find it highly and bitterly ironic that Teva fights companies that would make a generic version of Copaxone, from which they've been profiting handsomely for roughly 20 years.
Screw Teva. Let the generic glatiramer acetate proliferate.
Submitted by Anonymous (not verified) on Wed, 2009-04-01 13:08.
And this is not an academic argument: we all have 1 million dollar lifetime limits in coverage from insurance. I have been on copaxone since it came out, they have recieved at least one fourth of my lifetime limit, and I am sorry to say that though it helps me a little bit not nearly enough to justify the expense.
In addition to that there is the question as to whether the every other day dosing is just as effective as the every day. Another way they could have reduced costs significantly.
Teva Pharmaceuticals, the
Teva Pharmaceuticals, the maker of Copaxone, is known worldwide as a manufacturer of generic drugs. I find it highly and bitterly ironic that Teva fights companies that would make a generic version of Copaxone, from which they've been profiting handsomely for roughly 20 years.
Screw Teva. Let the generic glatiramer acetate proliferate.
Ah yes, I missed that sweet,
Ah yes, I missed that sweet, sweet irony myself. Thanks for pointing it out :-)
***
Art Mellor, Accelerated Cure Project for MS, art-msnews -at- acceleratedcure.com
And this is not an academic
And this is not an academic argument: we all have 1 million dollar lifetime limits in coverage from insurance. I have been on copaxone since it came out, they have recieved at least one fourth of my lifetime limit, and I am sorry to say that though it helps me a little bit not nearly enough to justify the expense.
In addition to that there is the question as to whether the every other day dosing is just as effective as the every day. Another way they could have reduced costs significantly.
That's a very good point I
That's a very good point I had never considered before.
***
Art Mellor, Accelerated Cure Project for MS, art-msnews -at- acceleratedcure.com